Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0CG0D
|
|||
Drug Name |
1,2-diamino cyclopentane-based derivative 33
|
|||
Synonyms |
PMID26593218-Compound-54
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
|
|||
Structure |
Download2D MOL |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Orexin receptor type 1 (HCRTR1) | Target Info | Antagonist | [1] |
Orexin receptor type 2 (HCRTR2) | Target Info | Antagonist | [1] | |
Target's Patent Info | Orexin receptor type 1 (HCRTR1) | Target's Patent Info | [1] | |
Orexin receptor type 2 (HCRTR2) | Target's Patent Info | [1] | ||
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Reactome | G alpha (q) signalling events | |||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.